# RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

> **NCT00632463** · PHASE2 · COMPLETED · sponsor: **ADMA Biologics, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection

## Interventions

- **BIOLOGICAL:** RI-001
- **BIOLOGICAL:** RI-001
- **BIOLOGICAL:** RI-001

## Key facts

- **NCT ID:** NCT00632463
- **Lead sponsor:** ADMA Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632463, "RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00632463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*